CClinicalTrials.gg
CompletedNCT04918394CHAMPIASTHMAUpdated Apr 22, 2026

Mold Exposure and Impact on Asthma Control in French Asthmatic Children

An observational study in Asthma in Children, sponsored by University Hospital, Lille. Completed at 10 sites in France. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by University Hospital, Lille · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
451
Ages
1 Year to 18 Years
Sex
All
01

Study summary

Observational, multicenter, study conducted in 12 hospitals in the Nord and Pas-De-Calais departments. The aim of this study is to describe the relationship between reported exposure to molds and asthma control in a pediatric population.

Each patient followed by a specialized asthma pediatrician in one of the study center will be proposed to participate in the study.

Children aged 1 to \< 18 years, with asthma diagnosis, based on the assessment of a specialized physician after a follow-up of at least 6 months Inclusion, non-inclusion and exclusion criteria will be verified by the investigators. The questionnaires will be completed during the consultation, collected by the physician in charge of the consultation and sent to the principal investigator for data entry.

Inclusion will take place over a period of 12 consecutive months from the date of obtaining regulatory approval.

02

Conditions studied

  • Asthma in Children

Browse trials for

Keywords

  • Asthma
  • Children
  • Mold
  • Moisture
  • Asthma Control
03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's enrollment of 451 is above the median of 150 across 970 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children follow-up by a specialized asthma pediatrician in secondary (general hospital) and tertiary care (Lille university hospital) centers.

Inclusion criteria

  • Children aged 1 to \< 18 years, with asthma diagnosis, based on the assessment of a specialized physician after a follow-up of at least 6 months, Follow-up in one of the study center in Nord and Pas de Calais departments (Lille, Lens, Tourcoing, Valenciennes, Arras, Roubaix, Seclin, Armentières, Calais, Boulogne/mer, Dunkerque, GHICL-Saint Vincent) over an inclusion period of 12 months

Exclusion criteria

Exclusion Criteria:

  • Children living ≤ 50% of the weekly time in their primary home (e.g., shared custody)
  • Children whose living arrangement characteristics are difficult to analyze (e.g., child accompanied by grandparents or by the parent without primary custody)
  • Children whose residence has recently changed, making it impossible to assess the impact of the living arrangement over the past year
  • Children living outside of the Nord and Pas-de-Calais departments
  • Children whose parents are unable to complete the questionnaire
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
451 participants (actual)
Patient registry
No

Groups and cohorts

  • Asthma patients unexposed to mold / moisture

    No mold / moisture exposure is defined by a negative response to all of the 5 following questions, asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home.

    Other: Questionnaire of Mold / moisture exposure

  • Asthma patients exposed to mold / moisture

    Mold / moisture exposure is defined by a positive response to at least one of the 5 following questions, asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home.

    Other: Questionnaire of Mold / moisture exposure

Interventions

  • OtherQuestionnaire of Mold / moisture exposure

    Mold / moisture exposure is assessed by the 5 following questions, whose positive response has been associated with the actual presence of mold in the household (according to data from the literature data), asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home: * Presence of visible mold * Impression of dampness * Apparent dampness * Existence of recent water damage in the last year * Presence of a moldy odor

06

What researchers measure

Primary outcomes

  1. Asthma control according to GINA guidelines

    The Global Initiative for Asthma (GINA)guidelines: Well controlled Partly controlled Uncontrolled

    Time frame: At the time of inclusion

Secondary outcomes

  1. Asthma control according to Asthma Control Test (ACT) score in children aged 12 years and older: Controlled if ACT ≥ 20

    Asthma Control Test: Each question is assigned a score between 1 and 5 (the score for the first answer proposal is 1, the second is 2, and so on). The score of the 5 questions is added up to a total score that can vary between 5 and 25. The higher the total score, the better the asthma is controlled.

    Time frame: At the time of inclusion

  2. Asthma control according to pACT score in children aged 1 to 11 years old: Controlled if ACT ≥ 20

    Time frame: At the time of inclusion

  3. Asthma treatment step according to GINA guidelines: Step 1 to step 4 in children aged < 6 years Step 1 to step 5 in children aged ≥ 6 years

    Time frame: At the time of inclusion

  4. Inhaled corticosteroid doses in µg/day of fluticasone

    Time frame: At the time of inclusion

  5. Acute asthma events in the past 12 months

    Acute asthma events: emergency room visits, hospitalization, general corticosteroid course

    Time frame: At the time of inclusion

  6. Exposure to other indoor pollutants: cigarette smoke (declarative smoking by at least one of the parents)

    Time frame: At the time of inclusion

  7. Exposure to indoor allergens: declarative exposure to animal danders

    Time frame: At the time of inclusion

  8. Exposure to indoor allergens: declarative exposure to house dust mite (carpet, mattress)

    Time frame: At the time of inclusion

07

Study locations

10 sites
  • Ch Armentieres
    Armentières, France
  • Ch Boulogne-Sur-Me
    Boulogne-sur-Mer, 62321, France
  • Ch Calais
    Calais, France
  • CH Dunkerque
    Dunkirk, 59385, France
  • Centre Hospitalier de Lens
    Lens, France
  • Hop Jeanne de Flandre Chu Lille
    Lille, 59037, France
  • Centre Hospitalier St Vincent
    Lille, France
  • Centre hospitalier de Roubaix
    Roubaix, France
  • Centre Hospitalier de Seclin
    Seclin, France
  • Centre Hospitalier,
    Valenciennes, France
08

References and documents

Publications

  • Sauvere M, Lejeune S, Chagnon F, Drumez E, Cisterne C, Mordacq C, Thumerelle C, Scalbert M, Le Mee A, Amani M, El Mourad S, Enchery S, Pouessel G, Roussel J, Dartus M, Behal H, Deschildre A. Home exposure to moisture and mold is associated with poorer asthma control in children: CHAMPIASTHMA study. J Allergy Clin Immunol Glob. 2025 Jan 17;4(2):100415. doi: 10.1016/j.jacig.2025.100415. eCollection 2025 May. PubMed 40130077 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04918394
Lead sponsor
University Hospital, Lille
Responsible party
Sponsor
First posted
Jun 8, 2021
Start date
Jun 10, 2020
Primary completion
Aug 20, 2021
Completion
Aug 20, 2021
Last update
Apr 22, 2026

Study contacts

Antoine DESCHILDRE, MD,PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion